AP 1102
/ Action Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 07, 2020
A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN
(clinicaltrials.gov)
- P2; N=23; Recruiting; Sponsor: SynAct Pharma Aps
Clinical • New P2 trial • Complement-mediated Rare Disorders • Renal Disease
July 02, 2019
SynAct-CS002: A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease
(clinicaltrials.gov)
- P2; N=90; Recruiting; Sponsor: SynAct Pharma Aps
Clinical • New P2 trial
1 to 2
Of
2
Go to page
1